Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular damaging agents.

D M Patterson1, G J S Rustin

  • 1Department of Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK. danpatterson@doctors.org.uk

Clinical Oncology (Royal College of Radiologists (Great Britain))
|April 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.

ESMO open·2021
Same author

The management of high-risk gestational trophoblastic tumours (GTT).

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2018
Same author

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.

British journal of cancer·2014
Same author

Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same journal

Research Trends in Physical Activity and Breast Cancer: A 25-Year Bibliometric Analysis (2000-2025).

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Concordance Between Planned and Delivered treatment for Head and Neck Cancer Patients Treated With Curative Intent: A Real-World Comparison of Under 70-year-olds With 70-year-olds and Over.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

A Novel Technique for Pain Management to Deliver a Course of Palliative Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Vascular targeting agents, including vascular disrupting agents (VDAs) and angiogenesis inhibitors (AIs), show promise in combination therapies. Radiobiological principles explain enhanced efficacy when combined with chemotherapy or radiotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Radiology

Background:

  • Vascular targeting agents are crucial in cancer therapy, categorized into vascular disrupting agents (VDAs) and angiogenesis inhibitors (AIs).
  • Current single-agent therapies with VDAs and AIs show limited success.
  • Combination therapies targeting both tumor and endothelial cells are necessary for improved outcomes.

Purpose of the Study:

  • To review vascular targeting agents and radiobiological principles in pre-clinical and clinical cancer studies.
  • To explore the synergistic potential of VDAs and AIs in combination treatments.
  • To understand how radiobiological principles can enhance the efficacy of these agents.

Main Methods:

  • Comprehensive literature review of published medical studies on vascular targeting agents using PubMed.

Related Experiment Videos

  • Analysis of pre-clinical and clinical data on VDAs and AIs.
  • Application of radiobiological principles to interpret treatment outcomes.

    • Main Results:

    • VDAs target existing tumor vasculature, while AIs inhibit new blood vessel formation.
    • Combination therapies involving VDAs and AIs demonstrate synergistic potential.
    • Radiobiological principles elucidate enhanced efficacy of combined treatments, particularly with chemotherapy or radiotherapy.
    • Phase II/III trials show encouraging results for combination therapies.

    Conclusions:

    • Combination therapies with vascular targeting agents (VDAs and AIs) are needed for enhanced anti-neoplastic effects.
    • Radiobiological principles support the improved efficacy of combination treatments by altering the tumor microenvironment.
    • Further research into the optimal use, scheduling, and mechanisms of action of VDAs and AIs is required.